文献速递眼底病与葡萄膜炎

ACCORD试验中糖尿病视网膜病变的发病率、进展与健康相关生活质量

Diabetic Retinopathy Incidence, Progression, and Health-Related Quality of Life From the ACCORD Trial.
PubMed 文献 · Am J Ophthalmol · 2025-07-23

本研究为回顾性队列研究,纳入ACCORD试验(n=6219)和ACCORD眼研究(n=1687)中糖化血红蛋白至少7.5%的2型糖尿病患者,评估健康相关生活质量(HRQOL)与糖尿病视网膜病变(DR)进展的关联。结果显示,自我报告发生DR者四年后EuroQoL感觉温度计、HUI-2、HUI-3及Brazier指数评分均显著低于未报告发生DR者;ACCORD眼研究中DR进展者仅HUI-3评分显著降低。

要点

  • DR发生与更差的主观总体健康、HUI-2、HUI-3及更多躯体健康干扰和抑郁相关。

核心结论

  • DR发生与更差的主观总体健康、更差的HUI-2、更差的HUI-3以及更多来自躯体健康和抑郁的干扰相关。
  • DR进展仅与第4年时HUI-3的下降相关。

研究设计与样本

  • 回顾性队列研究,纳入ACCORD试验(n=6219)和ACCORD眼研究(n=1687)中糖化血红蛋白至少7.5%的2型糖尿病患者。
  • 采用多变量线性回归调整基线HRQOL评分及人口学和临床协变量,比较随访4年后发生与未发生DR进展者最终HRQOL评分的差异。
  • ACCORD研究中DR发生由参与者自我报告;ACCORD眼研究中DR进展定义为在早期糖尿病视网膜病变治疗研究量表上≥3步个人尺度增加,或进展为需激光光凝或玻璃体切割的增殖性DR。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We performed a retrospective cohort study to evaluate the association between health-related quality-of-life (HRQOL) measures and diabetic retinopathy (DR) progression among participants of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial and the ACCORD Eye Study. DESIGN: Retrospective cohort. PARTICIPANTS: ACCORD (n = 6219) and ACCORD Eye (n = 1687) participants with type 2 diabetes mellitus with a glycated hemoglobin level of at least 7.5%. METHODS: HRQOL measures included the feeling thermometer (general health), Health Utilities Index Mark (HUI) 2 (aggregate score of sensation, mobility, cognition, self-care, emotion, pain, and fertility), HUI-3 (aggregate score of vision, hearing, speech, ambulation, dexterity, emotion, cognition, and pain), Patient Health Questionnaire-9 (PHQ-9) for depression, and Short Form-36, including the Aggregate Interference score derived from physical health and emotional problems (Brazier Index). Across all measures, a higher score indicated better HRQOL. Multivariable linear regression adjusted for baseline HRQOL scores as well as demographic and clinical covariates was used to compare the difference in final HRQOL scores after 4 years of follow-up between those who did and did not experience DR progression. MAIN OUTCOME MEASURES: DR development was self-reported by participants in the ACCORD study. DR progression in the ACCORD Eye study was defined as a ≥3-step person scale increase on the Early Treatment of Diabetic Retinopathy Study scale or progression to proliferative DR requiring laser photocoagulation or vitrectomy. RESULTS: Among ACCORD participants, those self-reporting DR development had a significantly lower score on the EuroQoL feeling thermometer by 3.68 points ([-4.91, -2.45], P < .001), HUI-2 by 0.02 points ([-0.03, -0.01], P = .005), HUI-3 by 0.04 points ([-0.06, -0.02], P < .001), and Brazier Index by 0.03 points ([-0.04, -0.01], P = .001) compared with those who did not report developing DR. Among ACCORD Eye participants, those with DR progression had a significantly lower score on HUI-3 by 0.05 points ([-0.09, -0.01], P = .022) compared with those who did not experience DR progression. CONCLUSIONS: DR development was associated with worse subjective general health, worse HUI-2, worse HUI-3, as well as more interference from physical health and depression. DR progression was only associated with a decrease in HUI-3 by year 4.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Prasad M, Agrón E, Vitale S, et al. Diabetic Retinopathy Incidence, Progression, and Health-Related Quality of Life From the ACCORD Trial. Am J Ophthalmol. 2025. PMID: 40712766. doi:10.1016/j.ajo.2025.07.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。